Floatz logo

lmp1/2 ctls

Hodgkin Disease

Catherine BollardCell therapyPhase 1Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB

View all 50 →

Same molecule, other indications

lmp1/2 ctls is also rated in:

nasopharyngeal type undifferentiated carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
leiomyosarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
Severe Chronic Active EBV Infection Syndrome (SCAEBV)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →